As per the research report, the size of the Asia Pacific Preimplantation Genetic Testing Market is valued at USD 112.23 million in 2021 and estimated to be growing at a CAGR of 14.13%, to reach USD 217.33 million by 2026 during the forecast period 2021 to 2026.
The growth of this market is mainly driven by the increasing rate of infertility in the world, the increase in the number of fertility clinics in the world, the public-private investments in the field of preimplantation genetic tests, the technological advances in the field of genetic analysis and the high risk of chromosomal abnormalities in the fetus with increasing maternal age.
The main factor attributed to the growth of the market is increased parental awareness of diagnostic advancements with high volume of neonatal deaths due to complications in childbirth. In recent years, the increasing prevalence of congenital genetic diseases and common pediatric respiratory disorders has been observed. These abnormalities occur almost exclusively in couples with inherited disorders, which have been found to occur mainly in industrialized countries. Therefore, the increased demand for early diagnosis and increased government efforts to control the burden of healthcare are likely to boost the market for preimplantation genetic testing.
Early diagnosis of chromosomal disorders helps reduce the number of people with congenital diseases. These factors are expected to drive demand for preimplantation genetic testing (PGT) market. It is estimated that the increasing number of incidences of various gene related disorders will support the market growth over the next coming years.
The high procedural cost associated with preimplantation genetic testing and unfavorable government regulations are the major factors limiting the growth of this market. Recently, PGT technology is integrated with Assisted Reproductive Technology (ART) procedures to deliver the best results to patients around the world. Technological advances and the relatively high accuracy of the results encourage a greater preference for this diagnostic modality. In addition, the detection of monogenic disorders is more beneficial than conventional prenatal diagnostic tests on embryos, which is driving the market for PGT. The poor healthcare infrastructure is expected to be the main challenge in developing countries of APAC region.
This research report on the Asia Pacific Preimplantation Genetic Testing Market has been segmented and sub-segmented into the following categories:
By Procedure Type:
By Products & Services:
By End User:
Known for providing excellent medical services at very economical rates compared to developed regions, the healthcare industry in Asia has invited patients from all over the world. With continuous advancements in healthcare infrastructure, an increasing number of healthcare experts, and constant improvement in diagnostic facilities, Asia is expected to be a major hub for the PGT market in the future. Many global healthcare and diagnostic providers are expanding their businesses in Asia and the number of fertility clinics, hospitals and diagnostic centers is steadily increasing in the region.
Fertility clinics held a significant share of the overall Asian PGD market in 2018, and are expected to post a CAGR of 5.5% during the period 2020-2027. The booming tourism industry in the region is leading to the establishment of an increasing number of IVF centers and health facilities, such as hospitals and diagnostic centers in the region.
In the coming years, the Asian PGT market is expected to experience the strongest growth in southern countries such as India and China. The high and increasing rate of infertility in South Asian countries, the increase in disposable income and the high percentage of women in the workforce will enable the region to present more attractive growth opportunities for the Asian IPR market.
Top companies leading in the APAC Preimplantation Genetic Testing Market profiled in the report are Illumina, Inc., Yikon Genomics, CooperSurgical, Oxford Gene Technology, Inc., Thermo Fisher Scientific, Inc., Rubicon Genomics, Inc., Agilent Technologies, Inc., Natera, Inc., Abbott Laboratories, PerkinElmer, Inc., and SciGene Corporation.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Procedure Type
5.1.2 Preimplantation Genetic Screening
5.1.3 Preimplantation Genetic Screening
5.1.4 Y-o-Y Growth Analysis, By Procedure Type
5.1.5 Market Attractiveness Analysis, By Procedure Type
5.1.6 Market Share Analysis, By Procedure Type
5.2.2 Next-Generation Sequencing
5.2.3 Polymerase Chain Reaction
5.2.4 Validation Biomarkers
5.2.5 Fluorescence in Situ Hybridization
5.2.6 Comparative Genomic Hybridization
5.2.7 Single-Nucleotide Polymorphism
5.2.8 Y-o-Y Growth Analysis, By Technology
5.2.9 Market Attractiveness Analysis, By Technology
5.2.10 Market Share Analysis, By Technology
5.3 Product and Service
5.3.2 Reagents and Consumables
5.3.4 Software and Services
5.3.5 Y-o-Y Growth Analysis, By Product and Service
5.3.6 Market Attractiveness Analysis, By Product and Service
5.3.7 Market Share Analysis, By Product and Service
5.4.3 Structural Chromosomal Abnormalities
5.4.4 Single Gene Disorders
5.4.5 X-Linked Disorders
5.4.6 HLA Typing
5.4.7 Gender Identification
5.4.8 Y-o-Y Growth Analysis, By Application
5.4.9 Market Attractiveness Analysis, By Application
5.4.10 Market Share Analysis, By Application
5.5 End users
5.5.2 Maternity Centers & Fertility Clinics
5.5.3 Hospitals, Diagnostic Labs, and Service Providers
5.5.4 Research Laboratories & Academic Institutes
5.5.5 Y-o-Y Growth Analysis, By End users
5.5.6 Market Attractiveness Analysis, By End users
5.5.7 Market Share Analysis, By End users
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Procedure type
220.127.116.11 By Technology
18.104.22.168 By Product and Service
22.214.171.124 By Application
126.96.36.199 By End user
6.1.4 Market Attractiveness Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Procedure type
220.127.116.11 By Technology
18.104.22.168 By Product and Service
22.214.171.124 By Application
126.96.36.199 By End user
6.1.5 Market Share Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Procedure type
220.127.116.11 By Technology
18.104.22.168 By Product and Service
22.214.171.124 By Application
126.96.36.199 By End user
6.5 South Korea
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Illumina, Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Thermo Fisher Scientific Inc.
8.3 Agilent Technologies, Inc.
8.4 Perkinelmer, Inc.
8.5 Coopersurgical, Inc.
8.6 ABBott Laboratories
8.7 Natera, Inc.
8.8 Rubicon Genomics, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures